Preferred Label : Fulzerasib;
NCIt synonyms : KRAS G12C Inhibitor GFH925; KRAS G12C Inhibitor IBI351;
NCIt definition : An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation, G12C,
with potential antineoplastic activity. Upon oral administration, fulzerasib selectively
targets, binds to and inhibits the activity of the KRAS G12C mutant, thereby inhibiting
KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes,
serves an important role in cell signaling, division and differentiation. Mutations
of KRAS may induce constitutive signal transduction leading to tumor cell growth,
proliferation, invasion, and metastasis.;
UNII : 6D5B7F245W;
CAS number : 2641747-54-6;
Molecule name : GFH-925; IBI-351; IBI 351; GFH 925;
NCI Metathesaurus CUI : CL1906487;
Origin ID : C199055;
UMLS CUI : C5855333;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
